Bevasiranib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBevasiranib
Drug Alias NameCand 5bevasiranibumBevasiranib sodium
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionVascular endothelial growth factor A inhibitorsRNA interference
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOpko Health Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOpko Health Inc
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaMacular Degeneration

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG